Topical Chemotherapy In Melanocytic Conjunctival Tumors: Clinical Insights From Published Evidence

To provide an educational overview of the clinical role of topical chemotherapy in the management of melanocytic conjunctival tumors, focusing on practical indications, effectiveness, and tolerability of mitomycin C and interferon alpha-2b as reported in the literature.

The abstract is based on published clinical experience regarding the use of topical chemotherapy in melanocytic conjunctival tumors, as reported across ophthalmic oncology and cornea subspecialty settings.

A narrative synthesis of published clinical reports describing the use of topical mitomycin C and interferon alpha-2b in melanocytic conjunctival tumors was performed. The review focused on clinical indications, therapeutic context, including use as primary or adjuvant treatment, lesion characteristics, and reported safety considerations. 

Published evidence indicates that topical chemotherapy represents a meaningful non-surgical option in selected melanocytic conjunctival tumors. Mitomycin C has been reported as particularly useful in diffuse, superficial, and intraepithelial disease, while its adjuvant use following surgical excision appears beneficial in nodular or invasive lesions. Interferon alpha-2b demonstrates favorable tolerability and is considered a valuable alternative in patients unable to tolerate mitomycin C. 

Topical chemotherapy can play an important role in selected cases of melanocytic conjunctival tumors, both as primary therapy and as an adjuvant to surgical management. Careful patient and lesion selection is essential to optimize therapeutic benefit while minimizing treatment-related toxicity. An individualized, lesion-directed strategy is essential to optimize outcomes while minimizing toxicity. Further prospective studies are warranted to refine treatment protocols and evaluate long-term results.